Marley Kayden crunches the numbers on Hims & Hers (HIMS) earnings and its worse-than-expected revenue growth. The stock plunged following the opening bell as investors question the telehealth company's guidance. Tim Biggam breaks down an example options trade that points to solid growth in the future, but acknowledges that years of double digit growth are "likely behind" Hims & Hers.